TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07020117: A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Sponsor: Aktis Oncology, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT07020117 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07020117 Rescue Dossier →